Page last updated: 2024-08-16

temozolomide and iniparib

temozolomide has been researched along with iniparib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Donawho, CK; Ellis, PA; Harlan, JE; Iyer, R; Johnson, EF; Ladror, US; Liu, X; Maag, DX; Palma, JP; Patterson, MJ; Penning, TD; Ready, DB; Shi, Y; Shoemaker, AR; Solomon, LR; Soni, NB; Surber, BW; Xu, AJ1
Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X1
Ahluwalia, MS; Blakeley, JO; Chi, AS; Desideri, S; Eichler, A; Grossman, SA; Mikkelsen, T; Nabors, LB; Ribas, IG; Rosenfeld, MR; Ye, X1

Trials

2 trial(s) available for temozolomide and iniparib

ArticleYear
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
    Journal of neuro-oncology, 2015, Volume: 125, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Treatment Outcome

2015
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 01-01, Volume: 25, Issue:1

    Topics: Benzamides; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome

2019

Other Studies

1 other study(ies) available for temozolomide and iniparib

ArticleYear
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays

2012